Figures computed from official regulatory filings — .
Analysttarget 15 USD (+27173%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 0.02% · short 108.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vaxxinity, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
24 buys46 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ray Sumita | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Powchik Peter | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prime Movers Lab Fund I LP | Sell | $41.9K | SEC |
| Prime Movers Lab Fund I LP | Sell | $17.3K | SEC |
| Prime Movers Lab Fund I LP | Sell | $8.6K | SEC |
| Prime Movers Lab Fund I LP | Sell | $15K | SEC |
| Prime Movers Lab Fund I LP | Sell | $10K | SEC |
| Prime Movers Lab Fund I LP | Sell | $7K | SEC |
| Prime Movers Lab Fund I LP | Sell | $1.7K | SEC |
| Prime Movers Lab Fund I LP | Sell | $953.2 | SEC |
| Prime Movers Lab Fund I LP | Sell | $4K | SEC |
| Prime Movers Lab Fund I LP | Sell | $36.4K | SEC |
| Prime Movers Lab Fund I LP | Sell | $4.1K | SEC |
| Prime Movers Lab Fund I LP | Sell | $6.1K | SEC |
| Prime Movers Lab Fund I LP | Sell | $3.5K | SEC |
| Prime Movers Lab Fund I LP | Sell | $9.9K | SEC |
| Prime Movers Lab Fund I LP | Sell | $2.4K | SEC |
| Powchik Peter | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Toledano Gabrielle B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Diamandis Peter | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HORNIG GEORGE R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ogilvie Landon E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Eade Katherine A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith James Alan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Diamandis Peter | Exercise | $56.3K | SEC |